###begin article-title 0
###xml 36 47 <span type="species:ncbi:11103">Hepatitis C</span>
The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
###end article-title 0
###begin p 1
Conceived and designed the experiments: JD LC. Performed the experiments: FH CW LC VR CM DD AP HD FL. Analyzed the data: LC ER. Contributed reagents/materials/analysis tools: SL JD SC ER. Wrote the paper: SL LC.
###end p 1
###begin p 2
###xml 76 93 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 95 98 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 184 187 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 377 380 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 579 582 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 655 658 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 866 869 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Two to three percent of the world's population is chronically infected with hepatitis C virus (HCV) and thus at risk of developing liver cancer. Although precise mechanisms regulating HCV entry into hepatic cells are still unknown, several cell surface proteins have been identified as entry factors for this virus. Among these molecules, the tetraspanin CD81 is essential for HCV entry. Here, we have identified a partner of CD81, EWI-2wint, which is expressed in several cell lines but not in hepatocytes. Ectopic expression of EWI-2wint in a hepatoma cell line susceptible to HCV infection blocked viral entry by inhibiting the interaction between the HCV envelope glycoproteins and CD81. This finding suggests that, in addition to the presence of specific entry factors in the hepatocytes, the lack of a specific inhibitor can contribute to the hepatotropism of HCV. This is the first example of a pathogen gaining entry into host cells that lack a specific inhibitory factor.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 206 209 206 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Lemon1">[1]</xref>
###xml 337 340 337 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Manns1">[2]</xref>
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 19 22 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Hepatitis C virus (HCV) infection is a global public health problem affecting over 130 million individuals worldwide; its symptoms including chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma [1]. Unfortunately, no vaccine is currently available to prevent new infections and the current treatments are not fully efficient [2]. Clearly, new therapeutic strategies are urgently required.
###end p 4
###begin p 5
###xml 341 344 341 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Bartosch1">[3]</xref>
###xml 346 349 346 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Hsu1">[4]</xref>
###xml 522 525 522 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Lindenbach1">[5]</xref>
###xml 527 530 527 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Wakita1">[6]</xref>
###xml 532 535 532 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Zhong1">[7]</xref>
###xml 191 194 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 273 276 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 388 391 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 456 459 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 594 599 <span type="species:ncbi:9606">human</span>
Over the past decade, due to the lack of a cell culture system supporting production of infectious virus particles, several surrogate models have been developed to facilitate analysis of the HCV life cycle. Among these models, pseudoparticles (HCVpp), consisting of native HCV envelope glycoproteins assembled onto retroviral core particles [3], [4] have been useful in investigating the HCV entry process. More recently, however, production of infectious HCV particles in cell culture (HCVcc) has finally become possible [5], [6], [7]. This powerful system is based on the transfection of the human hepatoma cell line Huh-7 with the cloned JFH1 genome that replicates and produces infectious particles.
###end p 5
###begin p 6
###xml 104 107 104 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-OpDeBeeck1">[8]</xref>
###xml 157 160 157 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Wakita1">[6]</xref>
###xml 399 402 399 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Dubuisson1">[9]</xref>
###xml 648 652 648 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Bartosch2">[10]</xref>
###xml 870 874 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Evans1">[11]</xref>
###xml 876 880 876 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Zheng1">[12]</xref>
###xml 1107 1111 1107 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Yang1">[13]</xref>
###xml 1286 1290 1286 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Evans1">[11]</xref>
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 143 146 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 382 385 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 538 541 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 638 641 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 720 723 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 856 859 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 964 967 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1090 1093 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1118 1123 <span type="species:ncbi:9606">human</span>
###xml 1189 1192 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1227 1232 <span type="species:ncbi:9606">human</span>
###xml 1242 1245 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCV encodes two envelope glycoproteins, E1 and E2, that interact to form a noncovalent E1E2 heterodimer [8] which is present at the surface of HCV particles [6], and is therefore the obvious candidate ligand for cellular receptor(s). Although the early steps of viral entry have yet to be elucidated, several cell-surface expressed molecules have been proposed as entry factors for HCV (reviewed in [9]). Among these molecules, the tetraspanin CD81 and the scavenger receptor class B type I (SR-BI) have been shown to play major roles in HCV entry. However, co-expression of these two molecules in non-hepatic cell lines does not lead to HCV entry [10], suggesting that additional molecule(s) are involved in control of HCV entry. Recently, the tight-junction components Claudins (CLDN-1, CLDN-6, CLDN-9) have been identified as additional key factors for HCV infection [11], [12]. Interestingly, CLDN-1 is the first entry factor shown to confer susceptibility to HCV when ectopically expressed in non-hepatic cells. Nevertheless, although CLDN-1 subcellular distribution seems to modulate HCV permissivity [13], some human cell lines expressing CD81, SR-BI and CLDN-1 remain resistant to HCV entry suggesting that one or more human-specific HCV entry factor(s) remain to be discovered [11].
###end p 6
###begin p 7
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Boucheix1">[14]</xref>
###xml 225 229 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Levy1">[15]</xref>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Levy2">[16]</xref>
###xml 458 462 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Rubinstein1">[17]</xref>
###xml 825 829 825 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin1">[18]</xref>
###xml 831 835 831 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin2">[19]</xref>
###xml 837 841 837 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Clark1">[20]</xref>
###xml 843 847 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Stipp1">[21]</xref>
###xml 849 853 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Stipp2">[22]</xref>
###xml 1000 1004 1000 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-SalaValdes1">[23]</xref>
###xml 1168 1172 1168 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Kolesnikova1">[24]</xref>
###xml 1174 1178 1174 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Stipp3">[25]</xref>
###xml 1180 1184 1180 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Zhang1">[26]</xref>
CD81 belongs to the tetraspanin family. Members of this family organize and regroup their associated transmembrane proteins and are involved in various functions such as cell morphology, motility, fusion and signalling [14], [15]. A major characteristic of tetraspanins is their ability to interact with each other and with other transmembrane proteins, thus building membrane multi-molecular complexes, collectively referred to as the tetraspanin web [16], [17]. Within this network of interactions, tetraspanins form primary complexes with a limited number of proteins termed tetraspanin partners. These primary interactions are direct, highly specific and occur at high stoichiometry. Two major partners have been identified for CD81, EWI-F (also called CD9P-1, FPRP or CD315) and EWI-2 (also called PGRL, IgSF8 or CD316) [18], [19], [20], [21], [22], which may provide a link between the tetraspanin web and the actin cytoskeleton by interacting with Ezrin, an Ezrin-Radixin-Moesin (ERM) protein [23]. Although its function is still unclear, EWI-2 seems to participate in the regulation of cellular functions such as aggregation, spreading, motility and migration [24], [25], [26].
###end p 7
###begin p 8
###xml 215 216 215 216 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">w</underline>
###xml 223 224 223 224 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</underline>
###xml 227 228 227 228 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</underline>
###xml 229 230 229 230 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</underline>
###xml 122 125 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 268 271 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
In this work, we identified a cleavage product of EWI-2, which associates with CD81 and inhibits its interaction with the HCV envelope glycoproteins. Most importantly, this molecule, that we called EWI-2wint (EWI-2 without its N-terminus), has an inhibitory effect on HCV entry, highlighting a potential new mechanism for the regulation of cellular invasion by this pathogen.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
###xml 55 58 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
A CD81 partner blocks the interaction between CD81 and HCV envelope glycoproteins
###end title 10
###begin p 11
###xml 342 346 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin1">[18]</xref>
###xml 348 357 348 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g001">Figure 1A</xref>
###xml 704 713 704 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g001">Figure 1A</xref>
###xml 718 725 718 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001866-t001">Table 1</xref>
###xml 918 922 918 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Cocquerel1">[27]</xref>
###xml 1197 1201 1197 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Higginbottom1">[28]</xref>
###xml 1349 1358 1349 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g001">Figure 1A</xref>
###xml 1505 1514 1505 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g001">Figure 1A</xref>
###xml 1942 1949 1942 1949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001866-t001">Table 1</xref>
###xml 1089 1094 <span type="species:ncbi:10090">mouse</span>
###xml 1096 1100 <span type="species:ncbi:10090">Cont</span>
###xml 1769 1772 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Tetraspanin microdomains are typically disrupted by Triton X-100 (TX), but are retained in less hydrophobic detergents such as Brij97 (Bj). In addition, the replacement of divalent cations (CaMg) by EDTA in the Brij97 lysis buffer causes a disruption of tetraspanin/tetraspanin interactions but conserves the tetraspanin/partner interactions [18] (Figure 1A). These biochemical properties allowed us to investigate whether the interaction between CD81 and E1E2 heterodimers is similar when CD81 is embedded or not in a tetraspanin web or in a primary complex. For this purpose, we analysed the interaction between E1E2 heterodimers and CD81 in several cell lines lysed in different detergent conditions (Figure 1A and Table 1). The E1E2 complexes were immobilized on agarose beads bound to a conformation-sensitive monoclonal antibody (mAb H53). Analysis of these agarose-bound complexes under non-reducing conditions [27] showed proper folding of the heterodimers in the different detergent conditions (data not shown). As positive and negative controls, we used anti-CD81 and irrelevant mouse (Cont) mAbs, respectively. A recombinant soluble form of the CD81 large extracellular loop (CD81-LEL) [28] was also used as a control. CD81 from Molt-4 and 293T cells interacted with E1E2 heterodimers under all detergent conditions, as did the CD81-LEL (Figure 1A). In contrast, CD81 from Daudi and Ramos cells did not interact with E1E2 heterodimers when tetraspanin webs or primary complexes were conserved (Figure 1A, Bj/CaMg and Bj/EDTA, respectively). Daudi cells also did not react with E1E2 glycoproteins derived from HCVpp (data not shown). Together, our results suggest that a CD81 partner, present on Daudi and Ramos cells, blocks the interaction between CD81 and HCV glycoproteins. Testing of other cell lines indicated that such a CD81 partner is probably also present in other cell lines such as A431, a squamous carcinoma cell line (Table 1).
###end p 11
###begin title 12
###xml 24 27 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The interaction between HCV glycoproteins and CD81 is blocked when CD81 interacts with partner protein(s).
###end title 12
###begin p 13
###xml 3 6 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 153 156 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 383 387 <span type="species:ncbi:10090">Cont</span>
A, HCV E1E2 heterodimers immobilized onto anti-E2 coated beads interacted with CD81 in all cells lysed in Triton X-100 (TX). However, the interaction of HCV-E1E2 with CD81 was blocked in Daudi and Ramos cells lysed in Brij (Bj). Maintenance of CD81 with other tetraspanins (T) and partners (P) is disrupted by the indicated lysis conditions, as diagrammed. Anti-CD81 and irrelevant (Cont) mAbs were used in immunoprecipitations as controls. Precipitation of CD81 was revealed by western blotting with the anti-CD81 5A6 mAb. CD81-LEL corresponds to the large extracellular loop of CD81 fused to the glutathione-S transferase. B, After cell surface biotinylation, the indicated cell lines were lysed with Bj/EDTA, immunoprecipitated with 5A6 mAb and the proteins revealed by Western blotting with HRP-conjugated streptavidin. The values on the right are molecular sizes in kilodaltons. C, EWI-2wint production is directly connected to EWI-2 expression. Daudi cells interfered with negative siRNA or EWI-2 siRNA were biotinylated, lysed in Bj/EDTA, immunoprecipitated with the anti-CD81 5A6 mAb or an anti-EWI-2 mAb (8A12) and blotted sequentially with HRP-conjugated streptavidin and 5A6 mAb.
###end p 13
###begin title 14
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 24 27 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
In vitro interaction of HCV E1E2 heterodimers with CD81 and expression of cell markers.
###end title 14
###begin p 15
The ratio [CD81 band intensity in E1E2 IP in Bj/EDTA buffer]/[CD81 band intensity in E1E2 IP in TX/EDTA buffer] was used to evaluate the E1E2/CD81 interaction: -, </=0.1; +/-, >0.1-0.7<; +,>/=0.7
###end p 15
###begin p 16
Expression of SR-BI and Claudin-1 detected by WB with Cla-1 mAb and JAY.8 polyclonal Ab, respectively. Amount of each protein was compared to Huh-7 cells. The ratio [protein band intensity of the cell line]/[protein band intensity of Huh-7 cell line] was used: -, <0.1; +/-, >/=0.1-0.4<; +, >/=0.4-1<; ++, >/=1. Actin proteins were used for normalization.
###end p 16
###begin p 17
Cell surface expression of CD81 and EWI-2 proteins detected by flow cytometry with 5A6 and 8A12 mAbs, respectively. Analyses gave mean fluorescence intensities (MFI) in the range of 3-6 for negative controls and intensities over 10 for specific stainings.
###end p 17
###begin p 18
###xml 72 81 72 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g001">Figure 1B</xref>
Expression detected by co-immunoprecipitation with CD81 as described in Figure 1B. The ratio [EWI-2wint band intensity]/[CD81 band intensity] was used to evaluate the expression of EWI-2wint: -, </=0.01; +/-, >0.01-0.1</=; +, >0.1
###end p 18
###begin p 19
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin1">[18]</xref>
###xml 359 363 359 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Stipp1">[21]</xref>
###xml 395 404 395 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g001">Figure 1B</xref>
###xml 448 452 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin2">[19]</xref>
###xml 454 458 454 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Stipp2">[22]</xref>
###xml 1076 1080 1064 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin1">[18]</xref>
###xml 1082 1086 1070 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Stipp1">[21]</xref>
###xml 1201 1210 1189 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g001">Figure 1C</xref>
###xml 1405 1412 1393 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001866-t001">Table 1</xref>
###xml 1912 1919 1900 1907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001866-t001">Table 1</xref>
###xml 2082 2085 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To identify the CD81 partner blocking the interaction between CD81 and E1E2, we performed co-immunoprecipitation experiments using Bj/EDTA lysates from surface biotinylated cells. Under these conditions, only partners directly associated in primary complexes co-precipitate with CD81. In all cell lines, a 70-kDa surface protein, corresponding to EWI-2 [18], [21] was co-precipitated with CD81 (Figure 1B). EWI-F, the second major CD81/CD9 partner [19], [22] was also co-precipitated with CD81 and CD9 in 293T cells. To confirm the specificity of EWI-2 and EWI-F, these proteins were immunoprecipitated with specific mAbs 8A12 and 1F11, respectively (data not shown). Additional bands were also observed in these cells, but the identity of the corresponding proteins is unknown. Interestingly, an additional approximately55 kDa surface protein co-precipitated with CD81 in Daudi and Ramos cells but not in Molt-4 and 293T cells. This protein, which we have named EWI-2wint, has been previously proposed as a cleavage product of EWI-2 that remains associated with CD81 and CD9 [18], [21]. Furthermore, transfection of EWI-2 siRNA into Daudi cells reduced both the expression of EWI-2 and of EWI-2wint (Figure 1C) demonstrating that EWI-2wint production is directly connected to EWI-2 expression. We performed additional co-immunoprecipitation experiments using different surface biotinylated cell lysates (Table 1). Co-immunoprecipitation of EWI-2wint with CD81 correlated with the inhibition of CD81-E1E2 interaction in mild detergents. Conversely, cells for which CD81 bound to E1E2 did not express this protein. It is worth noting that primary hepatocytes and hepatoma cells do not have detectable levels of EWI-2wint. We also analysed SR-BI and CLDN-1 expression in the same cell lines, and the lack of interaction between CD81 and E1E2 glycoproteins cannot be correlated with the absence of these molecules (Table 1, see squamous carcinoma, A431). Altogether, our results suggest that EWI-2wint probably corresponds to the CD81 partner blocking the interaction between CD81 and HCV glycoproteins.
###end p 19
###begin title 20
EWI-2wint corresponds to EWI-2 with its amino-terminus deleted
###end title 20
###begin p 21
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Stipp1">[21]</xref>
###xml 287 296 287 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g002">Figure 2A</xref>
###xml 310 319 310 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g002">Figure 2D</xref>
###xml 521 530 521 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g002">Figure 2A</xref>
###xml 904 908 904 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin1">[18]</xref>
###xml 1097 1105 1085 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g002">Figure 2</xref>
###xml 196 201 <span type="species:ncbi:9606">human</span>
To confirm that EWI-2wint is a cleavage product of EWI-2, we constructed an EWI-2 cDNA with a C-terminal FLAG epitope tag (EWI-2FLAG), as described previously [21]. CHO cells stably co-expressing human CD81 and EWI-2FLAG (CHO/CD81+EWI-2FLAG) were surface biotinylated, lysed in Bj/EDTA (Figure 2A) or TX/EDTA (Figure 2D) and analysed in immunoprecipitation experiments. Upon EWI-2FLAG coexpression with CD81, EWI-2wint was detected following anti-FLAG immunoprecipitation or co-immunoprecipitation with CD81 (wint-FLAG ; Figure 2A). These results and Western blotting analyses (data not shown) showed that EWI-2wint still contains the C-terminal FLAG epitope, making EWI-2wint an authentic cleavage product of EWI-2. It is interesting to note that EWI-2wint was not recognized by our anti-EWI-2 mAb and that only a small fraction of CD81 co-immunoprecipitated with EWI-2 products, as previously observed [18]. Two smaller proteins of approximately50, and 45 kDa, which remained associated with CD81 and probably correspond to additional cleavage products of EWI-2 were also detected (asterisks in Figure 2).
###end p 21
###begin title 22
EWI-2wint is a cleavage product of EWI-2.
###end title 22
###begin p 23
###xml 164 167 164 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 188 191 188 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
CHO cells were (co)-transfected with pcDNA3.1/CD81 and pcDNA3.1/EWI-2FLAG (A and D), with pcDNA3.1/wint-FLAG (B and E), or with pcDNA3.1/CD81 and pcDNA3.1/EWI-2FLAGfur (C and F). EWI-2FLAGfur corresponds to EWI-2FLAG in which a furin cleavage site has been engineered. After cell surface biotinylation, cells were lysed with Bj/EDTA (A-C) or TX/EDTA (D-F) and proteins were immunoprecipitated with the indicated mAbs. Proteins were revealed by Western blotting with HRP-conjugated streptavidin. Asterisks indicate additional cleavage products of EWI-2.
###end p 23
###begin p 24
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Stipp1">[21]</xref>
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Stipp1">[21]</xref>
###xml 357 365 357 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g003">Figure 3</xref>
EWI-2 belongs to a novel family of immunoglobulin (Ig) proteins, which also includes EWI-F/CD9P-1/PGRL, EWI-101/CD101/V7 and EWI-3/IgSF3 [21]. The members of this family share a conserved EWI motif and contain an ectodomain composed of V-type Ig domains, a transmembrane domain and a short highly charged cytoplasmic tail [21]. EWI-2 contains 4 Ig domains (Figure 3).
###end p 24
###begin title 25
Alignment of EWI-2 sequence and the deduced EWI-2wint sequence.
###end title 25
###begin p 26
Asterisk indicates the position at which an Arg (R) residue was introduced to make a furin cleavage site. Underlined amino acids correspond to the signal peptide of EWI-2. The four Ig domains are colored. Amino acid residues corresponding to the putative transmembrane domain are in italics and those corresponding to the cytoplasmic tail are bolded.
###end p 26
###begin p 27
###xml 388 395 388 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001866-t002">Table 2</xref>
###xml 763 770 763 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001866-t002">Table 2</xref>
###xml 874 882 874 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g003">Figure 3</xref>
###xml 1056 1057 1056 1057 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">w</underline>
###xml 1064 1065 1064 1065 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</underline>
###xml 1068 1069 1068 1069 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</underline>
###xml 1070 1071 1070 1071 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</underline>
To identify the sequence of EWI-2wint, EWI-2FLAG and wint-FLAG proteins were purified by immunoaffinity from a Triton X-100 lysate of CHO/CD81+EWI-2FLAG and fractionated by SDS-PAGE. The bands corresponding to EWI-2FLAG and wint-FLAG were excised after colloidal blue staining and digested with trypsin or V8 endoproteinase Glu C and the resulting peptides analysed by mass spectrometry (Table 2). Interestingly, only peptides matching with the N-terminal membrane distal Ig domain (Ig 1 domain) of EWI-2 were not present in the wint-FLAG band, suggesting that this domain may be absent in the EWI-2wint protein. Indeed, sequencing of purified proteins by Edman degradation revealed that the N-terminal sequence of EWI-2wint corresponds to the QAPTS amino acids (Table 2) residues 166 to 170, which are located within the spacer separating the Ig1 and Ig2 domains of EWI-2 (Figure 3). Altogether, these results indicate that EWI-2wint corresponds to EWI-2 without its Ig 1 domain. Following these results, we chose to name this protein EWI-2wint for EWI-2 without its N-terminus.
###end p 27
###begin title 28
Mass spectrometric analyses and N-terminal sequencing of EWI-2 and EWI-2wint proteins
###end title 28
###begin p 29
Tryp: trypsine; Glu-C: V8 endoproteinase Glu C
###end p 29
###begin title 30
###xml 27 30 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Expression of EWI-2wint in HCV target cells
###end title 30
###begin p 31
###xml 242 258 242 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g002">Figure 2B and 2E</xref>
###xml 765 768 765 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">166</sup>
###xml 791 799 791 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g003">Figure 3</xref>
###xml 886 889 886 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 1015 1018 1015 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 1080 1096 1080 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g002">Figure 2C and 2F</xref>
###xml 1250 1253 1250 1253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 1266 1275 1266 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g004">Figure 4D</xref>
###xml 1350 1353 1350 1353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 1402 1405 1402 1405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 1541 1550 1541 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g004">Figure 4D</xref>
###xml 1840 1849 1840 1849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g004">Figure 4A</xref>
###xml 1910 1919 1910 1919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g004">Figure 4B</xref>
###xml 1989 1998 1989 1998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g004">Figure 4C</xref>
###xml 2249 2257 2249 2257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g004">Figure 4</xref>
###xml 2361 2364 2361 2364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 2372 2381 2372 2381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g004">Figure 4D</xref>
###xml 2524 2528 2524 2528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin1">[18]</xref>
###xml 2675 2679 2675 2679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Kazarov1">[29]</xref>
###xml 2681 2685 2681 2685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Yang2">[30]</xref>
###xml 301 304 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To characterize EWI-2wint, we cloned it as a FLAG-tagged protein in an expression vector (pcDNA3.1/wint-FLAG). CHO cells transfected with pcDNA3.1/wint-FLAG produced EWI-2wint and the two additional cleavage products (asterisks), as shown in Figure 2B and 2E. To further test the role of EWI-2wint in HCV infection, we tried to obtain hepatoma cells (Huh-7) stably expressing EWI-2wint. However, despite several attempts, EWI-2wint expression in cellular clones could not be detected by cell surface biotinylation and immunoprecipitation or by western blotting experiments (data not shown), suggesting that this protein was poorly expressed in these cells. To circumvent this problem, we added a single Arg residue into the EWI-2FLAG sequence directly upstream to Q166 amino acid (asterisk, Figure 3), making an EWI-2FLAG protein with a RGRR cleavage motif for furin (pcDNA3.1/EWI-2FLAGfur), a trans-Golgi network associated endopeptidase. This strategy, when tested in CHO cells transfected with pcDNA3.1/EWI-2FLAGfur, yielded a high amount of the EWI-2wint protein, as shown in Figure 2C and 2F. Furthermore, EWI-2wint could be detected by direct immunoprecipitation or by co-immunoprecipitation with CD81 in Huh-7 cells stably expressing EWI-2FLAGfur (wint-FLAG, Figure 4D). Almost no whole EWI-2FLAG protein reached the surface of Huh-7/EWI-2FLAGfur cells, indicating that the cleavage of EWI-2FLAGfur by furin was highly efficient in these cells. It should be noted that at least one additional cleavage product of EWI-2FLAG (asterisk, Figure 4D) was detected as in CHO cells. The association of one or two additional cleavage products with the production of EWI-2wint suggests that the first cleavage of EWI-2 allows the unmasking of one or two additional sites that are not accessible in the whole protein. In contrast, Huh-7 cells (Figure 4A), Huh-7 stably transfected with the empty vector (pcDNA3.1, Figure 4B) or with EWI-2FLAG, expressing a N-terminal HA epitope (HAEWI-2FLAG, Figure 4C) were devoid of EWI-2wint. In Huh-7 cells stably transfected with HAEWI-2FLAG, the tagged molecule was detected following co-immunoprecipitation with CD81 or by direct immunoprecipitation with anti-FLAG or anti-HA mAbs, as compared to control cells (Figure 4). The anti-CD81 and anti-FLAG antibodies precipitated different amounts of wint-FLAG in Huh-7/EWI-2FLAGfur cells (Figure 4D). This might be due to differences in the affinity of the antibodies, as has been previously observed when EWI-2 and CD81 were coprecipitated [18]. Alternative possibilities are that i) homodimerization and heterodimerization of EWI-2 and CD81 modulate recognition by antibodies, as described [29], [30], ii) binding of the anti-FLAG mAb at the C-terminus of EWI-2wint induces a dissociation of the CD81/EWI-2wint complexes.
###end p 31
###begin title 32
EWI-2wint expression in Huh-7 cells.
###end title 32
###begin p 33
###xml 110 113 110 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
After cell surface biotinylation, Huh-7 cells (A) stably expressing pcDNA3.1 (B), HAEWI-2FLAG (C) or EWI-2FLAGfur (D) were lysed with Bj/EDTA and analyzed by immunoprecipitation with indicated mAbs. Proteins were revealed by Western blotting with HRP-conjugated streptavidin. The molecular weights of the prestained molecular ladder are indicated in KDa. The asterisk indicates an additional cleavage product of EWI-2. The band indicated by a light arrow likely corresponds to a dimer of CD81, and the band indicated by a full arrow to an unidentified EWI-2 associated protein.
###end p 33
###begin title 34
###xml 19 22 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
EWI-2wint inhibits HCV infection
###end title 34
###begin p 35
###xml 166 169 166 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Lindenbach1">[5]</xref>
###xml 171 174 171 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Wakita1">[6]</xref>
###xml 176 179 176 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Zhong1">[7]</xref>
###xml 222 225 222 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 370 379 370 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g005">Figure 5A</xref>
###xml 403 412 403 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g005">Figure 5B</xref>
###xml 529 532 529 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 583 592 583 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g005">Figure 5C</xref>
###xml 920 929 920 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g005">Figure 5D</xref>
###xml 1009 1012 1009 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 66 69 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 144 147 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 772 775 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1028 1031 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
We then sought to determine whether EWI-2wint is able to modulate HCV infection of Huh-7 target cells. Originally we used cell culture produced HCV particles (HCVcc) [5], [6], [7] to infect Huh-7 cells expressing EWI-2FLAGfur, HAEWI-2FLAG, pcDNA3.1 or naive Huh-7 cells. In the absence of a reporter gene in HCVcc, infection levels were evaluated by immunofluorescence (Figure 5A) and western blotting (Figure 5B), 40 h post-infection. Interestingly, we observed a reduction in HCVcc infection level in cells expressing EWI-2FLAGfur, whereas it remained unmodified in control cells (Figure 5C). It is worth noting that in HAEWI-2FLAG cells, the HCVcc infection level was similar to that of pcDNA3.1 cells, indicating that ectopic expression of HAEWI-2FLAG does not affect HCV infection. In addition, flow cytometry analyses ruled out any potential bias due to different levels of CD81 cell surface expression on clones (Figure 5D). Altogether, these results indicate that EWI-2wint produced in Huh-7/EWI-2FLAGfur cells inhibits HCV infection.
###end p 35
###begin title 36
EWI-2wint inhibits HCVcc infection.
###end title 36
###begin p 37
###xml 328 331 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 725 729 <span type="species:ncbi:10090">Cont</span>
Cell clones were infected with JFH1 HCVcc and infectivity was analyzed by indirect immunofluorescence with an anti-C mAb (A) or Western blotting with an anti-E2 mAb (B). The fields displayed in (A) contained similar numbers of cells. C, Infection levels were measured by quantification with NIH Image 1.62 of the intensities of HCV E2 bands. The results are presented as percentages of HCVcc infection relative to the infection of Huh-7/pcDNA3.1 cells. Infection levels of three independent experiments are reported as the mean with standard deviation bars. D, CD81 expression on the surfaces of cells expressing or not EWI-2wint. Cells were stained by using an anti-CD81 mAb (5A6) and secondary antibody conjugated with PE. Cont corresponds to Huh-7 cells that were stained only with the secondary antibody.
###end p 37
###begin title 38
###xml 17 20 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
EWI-2wint blocks HCV entry into target cells
###end title 38
###begin p 39
###xml 18 21 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The life cycle of HCV can be divided into three major steps : entry of the virus into its target cells by receptor-mediated endocytosis, cytoplasmic and membrane-associated replication of the RNA genome, and assembly and release of the progeny virions.
###end p 39
###begin p 40
###xml 285 288 285 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Wakita1">[6]</xref>
###xml 320 337 320 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g006">Figures 6A and 6B</xref>
###xml 655 664 655 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g006">Figure 6B</xref>
###xml 49 52 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 419 422 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 709 712 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1134 1137 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To analyze the effect of EWI-2wint expression on HCV genome replication, we compared the efficiency of RNA replication and virus production between transfected cell lines expressing or lacking EWI-2wint. We transfected equal amounts of RNA corresponding to the full-length JFH1 genome [6] into the different cell lines (Figures 6A and 6B). Immunofluorescence analyses of transfected cells showed similar positivity for HCV anti-core antibody at 40 h post-transfection. Flow cytometry analyses using an anti-NS3 mAb showed that, although slightly stronger in Huh-7 cells, viral expression was similar in cellular clones that lacked or expressed EWI-2wint (Figure 6B), indicating that EWI-2wint does not affect HCV genome replication. Next, to assess the effect of EWI-2wint on the assembly and/or egress of particles, the culture medium of each transfected cell line was harvested and used to infect naive Huh-7 cells. Through core-specific immunofluorescence staining, we found that Huh-7 cells were similarly infected by virus produced from all transfected cellular clones (data not shown), suggesting that EWI-2wint does not affect HCV assembly and release.
###end p 40
###begin title 41
###xml 38 41 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
EWI-2wint inhibits the entry stage of HCV life cycle by reducing the interaction between E1E2 and CD81.
###end title 41
###begin p 42
###xml 1305 1313 1303 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 1377 1380 1375 1378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 1442 1450 1440 1448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g001">Figure 1</xref>
###xml 1600 1603 1598 1601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 37 40 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 412 416 <span type="species:ncbi:10090">Cont</span>
###xml 530 533 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
A, EWI-2wint does not interfere with HCV replication. The indicated Huh-7 cell lines were transfected with the full-length JFH1 genome, and expression of the core antigen was evaluated at 40 h post-transfection. The displayed fields contained similar numbers of cells. B, NS3 expression in JFH-1 transfected cells. Cells were stained by using an anti-NS3 mAb (486-D39) and secondary antibody conjugated with PE. Cont corresponds to untransfected Huh-7 cells. C, Huh-7 cell lines were incubated for 3 h with virus pseudotyped with HCV envelope glycoprotein (HCVpp) or VSV G envelope protein (VSVpp). HCVpp were generated with envelope proteins from 1a (HCVpp 1a) or 2a (HCVpp 2a) genotype. The inoculum was then removed and the cells were further incubated. At 2 days post-inoculation, cells were lysed and processed to measure the luciferase activity. The luciferase activities were normalized for protein concentration in each cell lysate. The results are presented as relative percentages to HCVpp infectivity on Huh-7 cells. Results are reported as the mean+/-S.D. of three independent experiments. Pseudotyped particles produced in the absence of envelope proteins were used as controls. The mean fluorescence activity of such particles represented less than 2% of the activity measured for HCVpp. D, In vitro interaction of E1E2 heterodimers with CD81 from Huh-7/EWI-2FLAGfur and Huh-7/pcDNA3.1. This assay was performed as described in Figure 1. The ratio [CD81 band intensity in E1E2 IP in Bj/EDTA buffer]/[CD81 band intensity in E1E2 IP in TX/EDTA buffer] was 0,27 and 0,84 in Huh-7/EWI-2FLAGfur and Huh-7/pcDNA3.1, respectively.
###end p 42
###begin p 43
###xml 233 242 233 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g006">Figure 6C</xref>
###xml 550 559 550 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g006">Figure 6C</xref>
###xml 77 80 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 214 217 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 286 289 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 342 345 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 502 528 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 924 927 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Our observations indicate that EWI-2wint likely affects an early step in the HCV life cycle. To test this hypothesis, we analyzed the effect of EWI-2wint on the infectivity of retroviral particles pseudotyped with HCV E1E2 proteins (Figure 6C). Use of HCVpp enables the analysis of the HCV entry step. We generated particles pseudotyped with HCV envelope glycoproteins from 1a and 2a genotypes (HCVpp 1a and HCVpp 2a, respectively) and control particles pseudotyped with the envelope glycoprotein G of vesicular stomatitis virus (VSVpp). As shown in Figure 6C, HCVpp infectivity was reduced in cells expressing EWI-2wint whereas it remained unmodified in control cells. Expression of EWI-2wint in target cells had no effect on VSVpp infectivity. It is interesting to note that HAEWI-2FLAG expression slightly increased HCVpp and VSVpp infectivity. Altogether, our results indicate that EWI-2wint inhibits the entry stage of HCV lifecycle, likely by interacting with CD81.
###end p 43
###begin p 44
###xml 251 254 251 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 277 285 277 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g001">Figure 1</xref>
###xml 387 390 387 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 505 514 505 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g006">Figure 6D</xref>
###xml 40 43 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 136 139 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 667 670 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To determine whether the lower level of HCV infection observed in EWI-2wint producing cells resulted from a reduced interaction between HCV glycoproteins and CD81, we compared the interaction between E1E2 and CD81 in Huh-7/pcDNA3.1 and Huh-7/EWI-2FLAGfur cells, as detailed in Figure 1. Interestingly, our results demonstrated reduced interaction between E1E2 and CD81 in Huh-7/EWI-2FLAGfur cells lysed in Bj/EDTA which conserves tetraspanins/partners interactions, as compared to cells lysed in TX/EDTA (Figure 6D). In contrast, the binding of E1E2 to CD81 was similar in Huh-7/pcDNA3.1 cells in both detergent conditions. These data indicate that the inhibition of HCV infection by EWI-2wint correlates with its capacity to inhibit the interaction between E2 glycoprotein and CD81.
###end p 44
###begin p 45
###xml 110 117 110 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 213 222 213 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g007">Figure 7A</xref>
###xml 282 285 282 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 332 335 332 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 461 470 461 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g007">Figure 7B</xref>
###xml 489 497 489 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g006">Figure 6</xref>
###xml 582 591 582 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g007">Figure 7A</xref>
###xml 602 605 602 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 644 652 644 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g005">Figure 5</xref>
###xml 750 759 750 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g007">Figure 7B</xref>
###xml 770 773 770 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 896 900 896 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Kapadia1">[31]</xref>
###xml 66 69 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1008 1011 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
In order to carry out statistical analyses of EWI-2wint effect on HCV infection, we next generated JFH1-based Renilla luciferase (R-Luc) reporter HCVcc and infected Huh-7 cells that lacked or expressed EWI-2wint (Figure 7A). Cellular populations (pcDNA3.1, HAEWI-2FLAG and EWI-2FLAGfur POP) and individual cellular clones (EWI-2FLAGfur A1, A6, B14, C1) have been used in these experiments. In parallel, we infected these cells with HCVpp 1a, HCVpp 2a or VSVpp (Figure 7B), as described in Figure 6. Our results showed that EWI-2wint expression inhibits HCVcc infectivity up to 80% (Figure 7A; EWI-2FLAGfur A6) confirming our previous findings (Figure 5). It is noteworthy that EWI-2wint was less effective, reducing HCVpp infectivity only by 40-50% (Figure 7B; EWI-2FLAGfur A1), which might be due to slight differences between HCVpp and HCVcc in the entry stages, as recently reported by others [31]. Once again, this study shows that EWI-2wint expression in Huh-7 cells leads to a significant reduction of HCV infection.
###end p 45
###begin title 46
EWI-2wint inhibits the infection of both HCVcc and HCVpp.
###end title 46
###begin p 47
###xml 60 63 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 110 113 110 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
###xml 167 174 167 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 326 334 326 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001866-g006">Figure 6</xref>
A, Cellular populations (pcDNA3.1, HAEWI-2FLAG and EWI-2FLAGfur POP) and individual cellular clones (EWI-2FLAGfur A1, A6, B14, C1) were infected with HCVcc expressing Renilla luciferase (R-Luc). In parallel, these cells were infected with HCVpp 1a, HCVpp 2a or VSVpp expressing firefly luciferase (F-Luc) (B), as described in Figure 6. At 2 days post-infection, cells were lysed and processed to measure the luciferase activity. The luciferase activities were normalized for protein concentration in each cell lysate. The results are presented as relative percentages to HCVcc (A) and HCVpp (B) infectivity on Huh-7 cells. HCVpp infections (B) were also normalized to VSVpp infections on Huh-7 cells. Results are reported as the mean+/-S.D. of three independent experiments.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 89 92 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 154 157 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 229 232 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Here, we identified a novel CD81 associated protein, EWI-2wint, which is able to inhibit HCV entry into target cells by blocking the interactions between HCV glycoproteins and CD81. This finding indicates that the early steps of HCV entry into its target cells involve tight control of CD81 accessibility to the viral particle.
###end p 49
###begin p 50
###xml 508 511 508 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Bartosch1">[3]</xref>
###xml 513 516 513 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Hsu1">[4]</xref>
###xml 518 521 518 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Lindenbach1">[5]</xref>
###xml 523 526 523 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Wakita1">[6]</xref>
###xml 528 531 528 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Zhong1">[7]</xref>
###xml 533 537 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Bartosch2">[10]</xref>
###xml 539 543 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Koutsoudakis1">[32]</xref>
###xml 661 665 661 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Molina1">[33]</xref>
###xml 817 821 817 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Cormier1">[34]</xref>
###xml 823 827 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Flint1">[35]</xref>
###xml 829 833 829 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Koutsoudakis2">[36]</xref>
###xml 974 978 974 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Evans1">[11]</xref>
###xml 980 984 980 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Zheng1">[12]</xref>
###xml 986 990 986 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Meertens1">[37]</xref>
###xml 1682 1686 1682 1686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Bost1">[38]</xref>
###xml 1736 1740 1736 1740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Coffey1">[39]</xref>
###xml 1742 1746 1742 1746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Crotta1">[40]</xref>
###xml 1863 1867 1863 1867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-SalaValdes1">[23]</xref>
###xml 22 25 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 315 318 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 657 660 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 970 973 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1008 1011 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1601 1604 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1620 1623 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
EWI-2wint may inhibit HCV entry by reducing E1E2-CD81 interactions for a number of possible reasons. EWI-2wint may reduce CD81 accessibility to envelope glycoproteins by steric hindrance. Alternatively, the association of EWI-2wint with CD81 may induce conformational modifications in CD81, blocking the binding of HCV heterodimers. Although the exact role of CD81 in the course of virus infection is not well defined, it is a key molecule required for productive infection by HCVpp and HCVcc of Huh-7 cells [3], [4], [5], [6], [7], [10], [32]. Moreover, most recently CD81 was shown to be required for the infection of primary hepatocytes by serum-derived HCV [33]. Previous studies have suggested that CD81 may not be required for the first attachment step, but rather function as a post-attachment entry co-factor [34], [35], [36]. Very recently, it has been shown that CLDN-1, 6 and 9 membrane proteins localized at tight junctions, are additional entry factors for HCV [11], [12], [37], indicating that HCV entry might involve a complex multistep process. CD81 might potentially be required for a post-binding step such as escorting the particle into the endocytic pathway or priming it for the pH triggered fusion mechanism. The association of EWI-2wint with CD81 could block such entry stages. Since our preliminary results suggest that CD81 and EWI-2wint likely colocalize in an endosomal compartment (unpublished data), EWI-2wint might exert its inhibitory effect on CD81 functionality in the endosomes. In addition, EWI-2wint may interfere with actin polymerization potentially required for HCV entry. Indeed, HCV replication requires microtubule and actin polymerization [38] and CD81 engagement leads to actin rearrangement [39], [40]. Furthermore, it has also recently been shown that CD81 and EWI-2 interact with Ezrin, an actin-linking ERM protein [23]. Lastly, we cannot exclude the possibility that EWI-2wint blocks other signaling pathways necessary for viral entry.
###end p 50
###begin p 51
###xml 1309 1313 1309 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Boucheix1">[14]</xref>
###xml 1315 1319 1315 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Levy2">[16]</xref>
###xml 1106 1109 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
EWI-2wint is a cleavage product of the EWI-2 protein. The proteolytic cleavage of EWI-2 Ig1 domain occurs downstream of the RGR amino acids. A site directed mutagenesis analysis showed that RXR (where X is any amino acid) correspond to the consensus site recognized by the protease involved in this cleavage (unpublished data). Further analyses using protease inhibitors and small interference RNAs should enable us to identify this protease. Pulse-chase experiments in CHO cells showed that the cleavage occurs after N-glycan maturation (unpublished data), suggesting that it likely involves a Golgi resident protease. We showed that a RGRR furin cleavage motif made by insertion of an Arg residue into the EWI-2 sequence allows efficient production of EWI-2wint and additional cleavage product(s) in Huh-7 cells. As shown here, EWI-2 can be cleaved at RGR site to produce EWI-2wint, and it is likely that a furin-like protease may be responsible for this cleavage. Such a protease may be expressed differently among cell types, such that liver cells lacking the enzyme are consequently more sensitive to HCV infection. On the other hand, the accessibility of EWI-2 to protease(s) may be cell-type specific and might be modulated by other components of the tetraspanin webs that vary in different cell types [14], [16].
###end p 51
###begin p 52
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Cocquerel2">[41]</xref>
###xml 1022 1026 1022 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Evans1">[11]</xref>
###xml 1054 1061 1054 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001866-t001">Table 1</xref>
###xml 80 83 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 371 374 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 499 502 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 931 934 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 987 990 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1089 1092 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1254 1257 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Although several molecules have already been implicated in the entry process of HCV, it is likely that additional specific factors regulate its entry into hepatic cells [41]. Silencing of endogenous EWI-2 in Huh-7 cells did not significantly affect HCVcc infection (data not shown) indicating that while being a major partner of CD81, EWI-2 is likely not involved in the HCV entry process. Here, we showed that EWI-2wint, present in some cell lines and absent from hepatic cells, is able to inhibit HCV entry. The production of a mAb directed against EWI-2wint will be essential to further analyse the expression profile of EWI-2wint in various tissues and cell lines. Nevertheless, our results suggest that, in addition to the presence of specific entry factors in the hepatocytes such as CD81, SR-BI, CLDN-1 and additional unidentified molecule(s), the absence of a specific inhibitor can also contribute to the hepatotropism of HCV. Interestingly, 293T cells, that are permissive for HCV entry when they express CLDN-1 [11], do not express EWI-2wint (Table 1). Further experiments with HCV non permissive cells expressing all known positive entry factors will be necessary to determine if the silencing of endogenous EWI-2wint is sufficient to induce HCV permissivity.
###end p 52
###begin p 53
In conclusion, our observation constitutes a basis for the rational design of new antiviral molecules. Moreover, it represents a new mechanism that contributes to the regulation of the entry of a pathogen into a host cell.
###end p 53
###begin title 54
Materials and Methods
###end title 54
###begin title 55
Cells and antibodies
###end title 55
###begin p 56
###xml 47 51 47 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Cocquerel3">[42]</xref>
###xml 180 184 180 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Bartosch2">[10]</xref>
###xml 98 103 <span type="species:ncbi:9606">human</span>
U937-CD81 cells have been described previously [42]. Primary hepatocytes were isolated from three human foetal livers (Advanced Bioscience Resources, Inc, Alameda, CA). HepG2-CD81 [10] have been described previously and were kindly provided by F-L. Cosset.
###end p 56
###begin p 57
###xml 53 57 53 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Oren1">[43]</xref>
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin1">[18]</xref>
###xml 101 105 101 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin2">[19]</xref>
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Cocquerel4">[44]</xref>
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Flint2">[45]</xref>
###xml 283 287 283 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Maillard1">[46]</xref>
###xml 118 121 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 143 146 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 215 218 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 228 231 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The mAbs used in this study included: 5A6 (anti-CD81 [43]), 8A12 (anti-EWI-2 [18]), 1F11 (anti-EWI-F [19]), H53 (anti-HCV E2 [44]), 3/11 (anti-HCV E2, kindly provided by J. McKeating [45]), ACAP27 and 486-D39 (anti-HCV core and HCV NS3, respectively, kindly provided by JF Delagneau [46]). The anti-beta actin (clone AC-15), the M2 anti-FLAG epitope mAb and the M2 anti-FLAG affinity gel were from Sigma. The HA11 (anti-HA, Clone 16B12) mAb was from Covance. The anti-claudin-1 (JAY.8) was from Zymed Laboratories. The anti-SR-BI (Cla-1) was from BD Transduction Laboratories.
###end p 57
###begin title 58
Plasmids
###end title 58
###begin p 59
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin1">[18]</xref>
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin1">[18]</xref>
###xml 782 785 782 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fur</sup>
pcDNA3.1/CD81 plasmid has been described previously [18]. EWI-2 was FLAG-tagged (DYKDDDDK) at its C-terminus by polymerase chain reaction (PCR) amplification from template pCMVSport6/EWI-2 [18] and subcloned into a pcDNA3.1 vector (pcDNA3.1/EWI-2FLAG). Three Gly residues were introduced between EWI-2 and FLAG epitope sequences to increase epitope accessibility. Plasmid pcDNA3.1/wint-FLAG encoding EWI-2 signal peptide (amino acids 1-25) and EWI-2 amino acids 166-613 fused to FLAG tag was made by fusion-PCR from template pcDNA3.1/EWI-2FLAG. pcDNA3.1/HAEWI-2FLAG encodes EWI-2 signal peptide followed by HA9 epitope (YPYDVPDYA) tag fused to the entire sequence of EWI-2FLAG. Three Gly residues were also introduced between HA epitope and EWI-2FLAG sequence. In pcDNA3.1/EWI-2FLAGfur plasmid, an Arg residue was introduced between EWI-2 amino acids 165 and 166. Cloning details and oligonucleotide sequences are available upon request.
###end p 59
###begin title 60
Cell transfection
###end title 60
###begin p 61
CHO cells were transfected using ExGen500 (Eurogentec). CHO/CD81+EWI-2FLAG cell line was obtained by selection for 2 weeks with 500 microg/ml hygromycin and 800 microg/ml neomycin. The resulting cells were maintained in selection media as a polyclonal population. For stably transfected Huh-7 cells, cells were electroporated using the Gene Pulser apparatus (Bio-Rad) and neomycin was added 48 hours post-transfection at 600 microg/ml. After 2 weeks, isolated clones were split using selection cylinders and maintained in neomycin medium.
###end p 61
###begin title 62
CD81-E1E2 interaction assay
###end title 62
###begin p 63
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Cocquerel1">[27]</xref>
###xml 886 887 880 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 76 79 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 591 597 <span type="species:ncbi:9986">rabbit</span>
###xml 603 608 <span type="species:ncbi:10090">mouse</span>
###xml 679 685 <span type="species:ncbi:9986">rabbit</span>
###xml 691 696 <span type="species:ncbi:10090">mouse</span>
###xml 779 784 <span type="species:ncbi:10090">mouse</span>
###xml 796 800 <span type="species:ncbi:10090">Cont</span>
###xml 960 964 <span type="species:ncbi:10090">Cont</span>
COS-7 cells were infected with a recombinant adenovirus (Ad) expressing the HCV proteins E1, E2, p7 and NS2 (Ad/E1E2p7NS2, amino acids 171-1026) [27] at a multiplicity of 25PFU per cell. At 48 h post-infection, cells were washed twice with ice-cold Dulbecco's phosphate-buffered saline (D-PBS), and lysed in one of the following lysis buffers : 1% Brij97 in D-PBS with calcium and magnesium (Bj/CaMg) or with 2 mM EDTA (Bj/EDTA), 1% Triton X-100 in D-PBS with calcium and magnesium (TX/CaMg), or with 2 mM EDTA (TX/EDTA). Clarified lysates were then incubated with mAb H53 pre-adsorbed onto rabbit anti-mouse protein A-sepharose overnight at 4degreesC (beads-E1E2). In parallel, rabbit anti-mouse-protein A beads were incubated with mAb 5A6 (beads-CD81) or an irrelevant control mouse mAb (beads-Cont). Cell lines were lysed in Bj/CaMg, Bj/EDTA, TX/CaMg or TX/EDTA lysis buffer at 10x106 cells/ml, clarified and incubated with beads-E1E2, beads-CD81 and beads-Cont for 6 h at 4degreesC. After rinsing five times with the lysis buffer, complexes were eluted in non-reducing sample buffer, resolved by SDS-PAGE, and immunoblotted with mAb 5A6.
###end p 63
###begin title 64
Detection of cell surface biotinylated proteins
###end title 64
###begin p 65
###xml 48 52 48 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Charrin2">[19]</xref>
###xml 327 333 <span type="species:ncbi:9986">rabbit</span>
###xml 339 344 <span type="species:ncbi:10090">mouse</span>
Cells were biotinylated as previously described [19] with 0.2 mg/ml EZ-link-Sulpho-NHS-LC-biotin (Pierce), and lysed into Bj/EDTA or TX/EDTA containing protease inhibitors (Complete, Roche). Lysates were precleared for 2 h at 4degreesC with protein A-sepharose (Amersham Biosciences) then incubated with mAbs pre-adsorbed onto rabbit anti-mouse-protein A beads for 2 h at 4degreesC. After rinsing, complexes were eluted, resolved by SDS-PAGE, and immunoblotted with peroxidase-conjugated streptavidin (Vector).
###end p 65
###begin title 66
EWI-2 silencing
###end title 66
###begin p 67
###xml 142 167 142 167 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; AUUACAAGGACGACGAUGA 3&#8242;</named-content>
###xml 226 250 226 250 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GUUCUCCUAUGCUGUCUU 3&#8242;</named-content>
###xml 328 332 328 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-SalaValdes1">[23]</xref>
To silence the expression of endogenous EWI-2 protein, Daudi cells were electroporated with negative siRNA directed against the FLAG epitope (5' AUUACAAGGACGACGAUGA 3', Dharmacon) and EWI-2 siRNA directed against the sequence 5' GUUCUCCUAUGCUGUCUU 3' (Dharmacon) corresponding to nucleotide sequence 253-270 of the ORF of EWI-2 [23]. Daudi cells were electroporated at 4degreesC using the Gene Pulser apparatus (400V, 950uF). Seventy two hours post-transfection, cells were biotinylated, lysed in Bj/EDTA and immunoprecipitated with 5A6 and 8A12 mAbs. Immunoprecipitated proteins were revealed by Western blotting with peroxidase-conjugated streptavidin or 5A6 mAb.
###end p 67
###begin title 68
Flow cytometry analysis
###end title 68
###begin p 69
###xml 330 334 <span type="species:ncbi:9925">goat</span>
###xml 340 345 <span type="species:ncbi:10090">mouse</span>
###xml 625 629 <span type="species:ncbi:9925">goat</span>
###xml 635 640 <span type="species:ncbi:10090">mouse</span>
After trypsinization, transfected cells were fixed with Formalin Solution (formaldehyde 4%, Sigma) and permeabilized with PBS 0.2% BSA 0.05% Saponin. After rinsing with PBS 2% BSA 2 mM EDTA, cells were incubated 1 h at 4degreesC with 486-D39 anti-NS3 mAb. After rinsing with washing solution, cells were incubated with PE labeled goat anti-mouse (BD Pharmingen) for 45 min at 4degreesC, then washed and fixed with Formalin Solution. For CD81 staining, cells were detached with PBS 2 mM EDTA and incubated 1 h at 4degreesC with 5A6 anti-CD81 mAb. After rinsing with washing solution, cell lines were incubated with PE labeled goat anti-mouse for 45 min at 4degreesC, then washed and fixed with Formalin Solution (PFA 10%, Sigma). Cells stained only with the secondary antibodies were used as negative control. Labeled cells were analyzed using a FACS Beckman EPICS-XL MCL.
###end p 69
###begin title 70
Protein purification, mass spectrometry and N-terminal sequencing
###end title 70
###begin p 71
###xml 62 63 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
For purification of EWI-2FLAG and wint-FLAG, approximately2x108 CHO/CD81+EWI-2FLAG cells were lysed in 20 mM Tris-HCl, 150 mM NaCl, pH 7.6 (TBS), 1 mM EDTA and 1% Triton X-100 in the presence of protease inhibitors. Clarified cell lysates were precleared for 2 h at 4degreesC with protein A-sepharose and then incubated with an anti-FLAG M2 affinity gel for 2 h at 4degreesC. After five washes with TBS containing 0.2% Triton X-100 (TBS-T), FLAG-tagged proteins were eluted with 100 microg/ml FLAG peptide (Sigma) in TBS-T. Purified proteins were then precipitated with 5 volumes of acetone, incubated overnight at -20degreesC, and centrifugated. After rinsing with 80% acetone, proteins were resuspended in sample buffer, and resolved by SDS-PAGE. Colloidal blue stained bands corresponding to EWI-2FLAG and wint-FLAG were then excised from the gel, reduced, alkylated with iodoacetamide (10 mg/ml in NH4HCO3, 20 mM) and digested overnight with 50 ng trypsin (Promega) in 20 mM NH4HCO3, or 100 ng V8 endoproteinase Glu C (Roche) in 0.1 M phosphate buffer pH7.7. The resulting peptide mixture was eluted from the gel, desalted, and spotted on a Maldi plate with freshly dissolved alpha-cyano-4-hydroxycinnaminic acid (5 mg/ml in 50% CH3CN, 20 mM citric acid). The dried spot was then washed with 20 mM di-ammonium citrate pH 4.5. Mass spectrometry was performed with a MALDI-TOF Voyager-DE-STR (Applied Biosystems). Spots were analysed by setting the following parameters: positive and reflector modes, acceleration voltage of 20KV, grid voltage of 61%, 90 ns of delayed extraction, low mass gate 500 amu. The laser energy required to desorb/ionise the samples was kept at low value, compatible with a good signal/noise ratio. Spectra were calibrated externally by using the [M+H+] monoisotopics ions from trypsinized lyzozyme. The theoretical list of digested peptides was obtained using MS-Digest . For N-terminal sequencing, purified proteins were transferred to PVDF and stained with amido black. Blotted EWI-2FLAG and wint-FLAG were sequenced in a Procise 492 sequanator (Applied Biosystems) using pulsed-liquid method.
###end p 71
###begin title 72
JFH-1 infection
###end title 72
###begin p 73
###xml 206 209 206 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Wakita1">[6]</xref>
###xml 211 215 211 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Delgrange1">[47]</xref>
###xml 276 277 276 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 666 669 654 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">488</sup>
###xml 681 685 <span type="species:ncbi:9925">goat</span>
###xml 691 696 <span type="species:ncbi:10090">mouse</span>
###xml 844 848 <span type="species:ncbi:9925">goat</span>
###xml 854 857 <span type="species:ncbi:10116">rat</span>
###xml 1000 1004 <span type="species:ncbi:9925">goat</span>
###xml 1010 1015 <span type="species:ncbi:10090">mouse</span>
The plasmid pJFH1, containing the full-length cDNA of JFH1 isolate (genotype 2a) and kindly provided by T. Wakita (National Institute of Infectious Diseases, Japan), was used to generate HCVcc as described [6], [47]. Infectious titers of viral stocks were estimated between 105 and 106 focus-forming units per ml, based on immunofluorescent detection of infected foci following infection of Huh-7 cells with serial dilutions of viral stocks. Cell lines were incubated with HCVcc (m.o.i. = 1) for 2 h at 37degreesC, washed and, incubated for additional 40 h at 37degreesC. Infections were scored by indirect immunofluorescence with anti-C mAb ACAP27 followed by Alexa488-conjugated goat anti-mouse (Jackson Immunoresearch). Fifteen micrograms of total protein were also analyzed by immunoblotting with 3/11 mAb followed by peroxidase-conjugated goat anti-rat immunoglobulins (Jackson Immunoresearch). The blots were then stripped and reprobed with an anti-beta actin followed by peroxidase-conjugated goat anti-mouse immunoglobulins (Sigma). Quantification of protein expression was performed using NIH Image 1.62 from the band mean densities.
###end p 73
###begin p 74
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Tscherne1">[48]</xref>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Delgrange1">[47]</xref>
###xml 258 261 258 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Wakita1">[6]</xref>
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Delgrange1">[47]</xref>
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Tscherne1">[48]</xref>
###xml 519 526 507 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 122 126 <span type="species:ncbi:4530">Rice</span>
###xml 173 176 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To generate HCVcc expressing Renilla luciferase, we used the FL-J6/JFH-5'C19Rluc2AUbi genome [48] kindly provided by C.M. Rice. We replaced the region encoding the J6/JFH-1 HCV polyprotein with the CS-N6 JFH-1 sequence [47]. HCVcc were produced as described [6], [47], [48]. HCVcc were added to Huh-7 cells (m.o.i. = 1) seeded the day before in 24-well plates and incubated for 2 h at 37degreesC. The supernatants were then removed and the cells were incubated in DMEM 10% FBS at 37degreesC. At 40-48 h post-infection, Renilla luciferase assays were performed as indicated by the manufacturer (Promega).
###end p 74
###begin title 75
HCVcc replication analyses
###end title 75
###begin p 76
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Kato1">[49]</xref>
In vitro transcribed full-length JFH1 RNA was transfected by electroporation as described [49]. At 40 h post-transfection, cells were analyzed by indirect immunofluorescence and flow cytometry.
###end p 76
###begin title 77
Indirect immunofluorescence microscopy
###end title 77
###begin p 78
###xml 200 203 200 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">488</sup>
###xml 215 219 <span type="species:ncbi:9925">goat</span>
###xml 225 230 <span type="species:ncbi:10090">mouse</span>
Infected or transfected cells grown on coverslips were fixed with 3% paraformaldehyde and permeabilized with 0.05% Triton X-100 in PBS. Cells were then stained with anti-C mAb ACAP27 followed by Alexa488-conjugated goat anti-mouse (Jackson Immunoresearch). Coverslips were mounted on glass slides using Mowiol, and observed with a Zeiss Axioplan 2 Axiophot 2 equipped with a 20x/1.3 numerical aperture lens. Fluorescent signals were collected with a Princeton cooled charged device using specific fluorescence excitation and emission filters. Images were processed with Adobe Photoshop software.
###end p 78
###begin title 79
Production of HCVpp and infection assays
###end title 79
###begin p 80
###xml 44 47 44 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Bartosch1">[3]</xref>
###xml 49 53 49 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-OpDeBeeck2">[50]</xref>
###xml 238 242 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001866-Sandrin1">[51]</xref>
###xml 196 222 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
HCVpp were produced as described previously [3], [50] with plasmids kindly provided by B. Bartosch and F.L. Cosset (INSERM U412, Lyon, France). For the production of VSVpp, a plasmid encoding the vesicular stomatitis virus glycoprotein G [51] was used. Supernatants containing the pseudotyped particles were harvested 48 h after transfection, filtered through 0.45-microm pore-sized membranes and conserved at 4degreesC. HCVpp were added to Huh-7 cells seeded the day before in 24-well plates and incubated for 2-3 h at 37degreesC. The supernatants were then removed and the cells were incubated in DMEM 10% FBS at 37degreesC. At 48 h post-infection, luciferase assays were performed as indicated by the manufacturer (Promega).
###end p 80
###begin p 81
###xml 238 242 <span type="species:ncbi:4530">Rice</span>
We thank Sophana Ung for his excellent technical assistance. We thank Cecile Voisset, Karin Seron and Hann-Shuin Yew for critical reading of the manuscript. We are grateful to J. McKeating, T. Wakita, J-F. Delagneau, F-L. Cosset and C.M. Rice for providing us with reagents.
###end p 81
###begin title 82
References
###end title 82
###begin article-title 83
###xml 0 11 <span type="species:ncbi:11103">Hepatitis C</span>
Hepatitis C Virus.
###end article-title 83
###begin article-title 84
###xml 15 26 <span type="species:ncbi:11103">hepatitis C</span>
Treating viral hepatitis C: efficacy, side effects, and complications.
###end article-title 84
###begin article-title 85
###xml 18 29 <span type="species:ncbi:11103">hepatitis C</span>
Highly infectious hepatitis C pseudo-viruses containing functional E1E2 envelope protein complexes.
###end article-title 85
###begin article-title 86
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.
###end article-title 86
###begin article-title 87
###xml 24 41 <span type="species:ncbi:11103">hepatitis C virus</span>
Complete replication of hepatitis C virus in cell culture.
###end article-title 87
###begin article-title 88
###xml 25 42 <span type="species:ncbi:11103">hepatitis C virus</span>
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.
###end article-title 88
###begin article-title 89
###xml 7 24 <span type="species:ncbi:11103">hepatitis C virus</span>
Robust hepatitis C virus infection in vitro.
###end article-title 89
###begin article-title 90
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
Biogenesis of hepatitis C virus envelope glycoproteins.
###end article-title 90
###begin article-title 91
###xml 19 36 <span type="species:ncbi:11103">hepatitis C virus</span>
Early steps of the hepatitis C virus life cycle.
###end article-title 91
###begin article-title 92
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.
###end article-title 92
###begin article-title 93
###xml 15 32 <span type="species:ncbi:11103">hepatitis C virus</span>
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.
###end article-title 93
###begin article-title 94
###xml 63 80 <span type="species:ncbi:11103">hepatitis C virus</span>
Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus.
###end article-title 94
###begin article-title 95
###xml 92 95 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Correlation of the tight junction-like distribution of claudin-1 to the cellular tropism of HCV.
###end article-title 95
###begin article-title 96
Tetraspanins.
###end article-title 96
###begin article-title 97
The tetraspanin web modulates immune-signalling complexes.
###end article-title 97
###begin article-title 98
Protein-protein interactions in the tetraspanin web.
###end article-title 98
###begin article-title 99
CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins.
###end article-title 99
###begin article-title 100
EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells.
###end article-title 100
###begin article-title 101
The major CD9 and CD81 molecular partner. Identification and characterization of the complexes.
###end article-title 101
###begin article-title 102
PGRL is a major CD81-associated protein on lymphocytes and distinguishes a new family of cell surface proteins.
###end article-title 102
###begin article-title 103
EWI-2 is a major CD9 and CD81 partner and member of a novel Ig protein subfamily.
###end article-title 103
###begin article-title 104
FPRP, a major, highly stoichiometric, highly specific CD81- and CD9- associated protein.
###end article-title 104
###begin article-title 105
EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton through their direct association with ezrin-radixin-moesin proteins.
###end article-title 105
###begin article-title 106
EWI-2 modulates lymphocyte integrin alpha4beta1 functions.
###end article-title 106
###begin article-title 107
EWI-2 regulates alpha3beta1 integrin-dependent cell functions on laminin-5.
###end article-title 107
###begin article-title 108
EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells.
###end article-title 108
###begin article-title 109
###xml 22 39 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 63 68 <span type="species:ncbi:9606">human</span>
Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody.
###end article-title 109
###begin article-title 110
###xml 76 93 <span type="species:ncbi:11103">hepatitis C virus</span>
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2.
###end article-title 110
###begin article-title 111
An extracellular site on tetraspanin CD151 determines alpha 3 and alpha 6 integrin-dependent cellular morphology.
###end article-title 111
###begin article-title 112
Contrasting effects of EWI proteins, integrins, and protein palmitoylation on cell surface CD9 organization.
###end article-title 112
###begin article-title 113
###xml 14 25 <span type="species:ncbi:11103">Hepatitis C</span>
Initiation of Hepatitis C Virus Infection Is Dependent on Cholesterol and Cooperativity between CD81 and Scavenger Receptor B Type I.
###end article-title 113
###begin article-title 114
###xml 87 104 <span type="species:ncbi:11103">hepatitis C virus</span>
The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.
###end article-title 114
###begin article-title 115
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 53 58 <span type="species:ncbi:9606">human</span>
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent.
###end article-title 115
###begin article-title 116
###xml 32 49 <span type="species:ncbi:11103">hepatitis C virus</span>
CD81 is an entry coreceptor for hepatitis C virus.
###end article-title 116
###begin article-title 117
###xml 30 47 <span type="species:ncbi:11103">hepatitis C virus</span>
Diverse CD81 proteins support hepatitis C virus infection.
###end article-title 117
###begin article-title 118
###xml 39 56 <span type="species:ncbi:11103">hepatitis C virus</span>
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses.
###end article-title 118
###begin article-title 119
###xml 77 94 <span type="species:ncbi:11103">Hepatitis C virus</span>
The tight junction proteins claudin-1, -6 and -9 are entry cofactors for the Hepatitis C virus.
###end article-title 119
###begin article-title 120
###xml 30 47 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 49 52 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 75 78 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Cytoskeletal requirements for hepatitis C virus (HCV) RNA synthesis in the HCV replicon cell culture system.
###end article-title 120
###begin article-title 121
###xml 47 58 <span type="species:ncbi:11103">Hepatitis C</span>
Co-ligation of CD81 and the B-cell receptor by Hepatitis C Virus envelope protein E2 enhances B-cell signaling.
###end article-title 121
###begin article-title 122
Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells.
###end article-title 122
###begin article-title 123
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus entry: potential receptors and their biological functions.
###end article-title 123
###begin article-title 124
###xml 26 43 <span type="species:ncbi:11103">hepatitis C virus</span>
CD81-dependent binding of hepatitis C virus E1E2 heterodimers.
###end article-title 124
###begin article-title 125
TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins.
###end article-title 125
###begin article-title 126
###xml 119 136 <span type="species:ncbi:11103">hepatitis C virus</span>
A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2.
###end article-title 126
###begin article-title 127
###xml 20 37 <span type="species:ncbi:11103">hepatitis C virus</span>
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.
###end article-title 127
###begin article-title 128
###xml 30 47 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients.
###end article-title 128
###begin article-title 129
###xml 91 108 <span type="species:ncbi:11103">hepatitis C virus</span>
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins.
###end article-title 129
###begin article-title 130
###xml 46 63 <span type="species:ncbi:11103">hepatitis C virus</span>
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry.
###end article-title 130
###begin article-title 131
###xml 41 58 <span type="species:ncbi:11103">hepatitis C virus</span>
Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon.
###end article-title 131
###begin article-title 132
###xml 31 48 <span type="species:ncbi:11103">hepatitis C virus</span>
Characterization of functional hepatitis C virus envelope glycoproteins.
###end article-title 132
###begin article-title 133
###xml 187 192 <span type="species:ncbi:9606">human</span>
Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates.
###end article-title 133
###begin p 134
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 134
###begin p 135
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by the "Institut Federatif de Recherche-142" (IFR142) and by grants from the CNRS and the << Agence Nationale de Recherches sur le Sida et les hepatites virales >> ANRS. V R-P was supported by a fellowship from the << Institut Pasteur de Lille/Region Nord Pas-de-Calais >>. DD was supported by a fellowship from the ANRS. FH was supported by a fellowship from the French Ministry of Research. JD is an international scholar of the Howard Hughes Medical Institute.
###end p 135

